课题基金 / 基金详情

Development of new cancer immunotherapy using activation of Toll like receptor against gastrointestinal cancer

Development of new cancer immunotherapy using activation of Toll like receptor against gastrointestinal cancer
利用Toll样受体激活对抗胃肠道癌症开发新的癌症免疫疗法
批准号:
18591479
负责人:
MATSUDA Kenji
金额:
$2.14万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

MATSUDA Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CpG oligodeoxynucleotides (CpG-ODNs) mimic bacterial DNA and induce immune response that comprise innate immunity and acquired Th-1 biased cellular immunity. Recently, 3 types of CpG-ODNs (CpG-A, CpG-B and CpG-C) have been identified based on distinct immunologic activities on human plasmacytoid dendritic cells (PDCs) and B cells. We investigated the activity of these three types of CpG-ODN to enhance the induction of peptide specific CTLs. First, human PBMCs of healthy volunteers were stimulated with each types of CpG-ODN for 48 hours. Samples of the culture media were analyzed for cytokine induction with ELISA method. CpG-A and CpG-C, but not CpG-B, were potent inducers of IFN-α. Second, Flu peptide-specific CTLs were generated from PBMCs cultured with Flu peptide and each types of CpG-ODN for 2 weeks to compare the lytic activity against A24-LCL cells pulsed with Flu peptide in a standard Cr lysis assay. Flu peptide-specific cytotoxicity was enhanced in the presence of each type of CpG-ODN and especially CpG-A and CpG-C showed higher lytic activity than CpG-B. This CpG ODN-induced enhancement of cytotoxicity was disappeared when PDCs were depleted from PBMCs. In conclusion, our results showed that CpG-A and CpG-C might be the superior vaccine adjuvant to CpG-B at least in vitro.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Streptococcal preparation OK-432 promotes the capacity of dendritic cells(DCs) to prime carcinoembryonic antigen(CEA)-specific T lymphocyte responses induced with genetically modified DCs that express CEA
链球菌制剂 OK-432 促进树突状细胞 (DC) 启动表达 CEA 的转基因 DC 诱导的癌胚抗原 (CEA) 特异性 T 淋巴细胞反应的能力
DOI: --
发表时间: 2008
期刊: Int J Oncol 32(2)
影响因子: --
作者: [Ojima T, et. al.]
通讯作者: et. al.
Successful cancer vaccine therapy for carcinoembryonic antigen(CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice
使用表达 CEA 和 T 辅助型 1 细胞因子的转基因树突状细胞在 CEA 转基因小鼠中成功治疗表达癌胚抗原 (CEA) 的结肠癌
DOI: --
发表时间: 2007
期刊: Int J Cancer 120(3)
影响因子: --
作者: [Ojima T, et. al.]
通讯作者: et. al.
Difference between CpG-A, CpG-B and CpG-C about the adjuvant effect to enhance human peptide-specific CTL induction in vitro
CpG-A、CpG-B和CpG-C在体外增强人肽特异性CTL诱导的佐剂作用的差异
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Katsuda M, et. al.]
通讯作者: et. al.
Repeat reduction surgery after an initial hepatectomy for patients with colotectal cancer
结肠直肠癌患者初次肝切除术后重复减容手术
DOI: --
发表时间: 2007
期刊: Oncology Reports 18
影响因子: --
作者: [Matsuda K, et. al.]
通讯作者: et. al.
12
    Molecular Electronics of Open-Shell Molecule Based on Spin-Dependent Photoexcited State Dynamics
    • 批准号:
      19H02788
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.15万
    • 财政年份:
      2019
    • 负责人:
      MATSUDA Kenji
    • 依托单位:
    Rational design and synthesis of pi-conjugated wire which shows high efficiency and low attenuation of electron tunneling
    • 批准号:
      15H03794
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.98万
    • 财政年份:
      2015
    • 负责人:
      MATSUDA Kenji
    • 依托单位:
    Photochromic electronic device using photoresponsive charge transport layer
    • 批准号:
      15K13669
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2015
    • 负责人:
      MATSUDA Kenji
    • 依托单位:
    New Aspects of Rebound Hardness Testing Method
    • 批准号:
      25630039
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.58万
    • 财政年份:
      2013
    • 负责人:
      MATSUDA Kenji
    • 依托单位:
    国内基金
    海外基金
    CircSLTM及其编码多肽SLTM-99aa通过SAFB介导的mRNA剪接重塑在胃癌发生发展中的分子机制及其临床价值研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      胡柯峰
    • 依托单位:
    多囊卵巢综合征中甲酰肽受体2调控小胶质细胞代谢重编程导致GnRH神经元过度激活及HPO轴异常的病理机制研究
    • 批准号:
      82370797
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      陶弢
    • 依托单位:
    Peptide YY调控Hippo/YAP通路促进皮肤组织创面愈合的机制研究
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      王晓
    • 依托单位:
    靶向促黏多肽R-Peptide对iPSCs来源肝脏类器官培养体系的优化及机制研究
    • 批准号:
      32160230
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      36.00万元
    • 批准年份:
      2021
    • 负责人:
      姚佳
    • 依托单位: